Mechanobiology June 26th - June 2nd 2016

Mechanobiology: June 26th  - June 2nd 2016


Key components of DNA replication and the basal transcriptional machinery as well as several tissue-specific transcription factors are compartmentalized in specialized nuclear domains. In the present study, we show that determinants of subnuclear targeting of the bone-related Runx2/Cbfa1 protein reside in the C-terminus. With a panel of C-terminal mutations, we further demonstrate that targeting of Runx2 to discrete subnuclear foci is mediated by a 38 amino acid sequence (aa 397-434). This nuclear matrix-targeting signal (NMTS) directs the heterologous Gal4 protein to nuclear-matrix-associated Runx2 foci and enhances transactivation of a luciferase gene controlled by Gal4 binding sites. Importantly, we show that targeting of Runx2 to the NM-associated foci contributes to transactivation of the osteoblast-specific osteocalcin gene in osseous cells. Taken together, these findings identify a critical component of the mechanisms mediating Runx2 targeting to subnuclear foci and provide functional linkage between subnuclear organization of Runx2 and bone-specific transcriptional control.


Multi-component macromolecular complexes that execute the fundamental nuclear processes of DNA replication, transcription and splicing are organized in discrete subnuclear foci (Lawrence et al., 1989; Nickerson et al., 1995; Stein et al., 2000; Wei et al., 1998; Wei et al., 1999). Specificity of gene expression is conferred by transcription factors that respond to physiological cues and intracellular signals. Many cell-type-restricted transcription factors are targeted to multi-subunit complexes that reside in distinct subnuclear domains (Bidwell et al., 1998; DeFranco and Guerrero, 2000; Stein et al., 2000), and support activation or repression of tissue-specific genes. These macromolecular complexes involved in transcription are dynamic, yet remain stably associated with the nucleus following removal of soluble proteins and chromatin. Examples of regulatory proteins that are targeted to intranuclear foci are Runx/Cbfa/AML factors (Merriman et al., 1995; Stein et al., 2000; Zeng et al., 1997; Zeng et al., 1998), the multi-functional YY1 protein (Guo et al., 1995; McNeil et al., 1998), steroid hormone receptors (glucocorticoid receptor, estrogen receptor, vitamin D receptor, androgen receptor) (DeFranco and Guerrero, 2000; Getzenberg et al., 1991; Getzenberg and Coffey, 1990; Stenoien et al., 2001; van Steensel et al., 1995a; van Steensel et al., 1995b), Pit1 transcription factor (Mancini et al., 1999), the corepressor transducin-like enhancer (TLE; Javed et al., 2000), histone deacetylases and acetyl transferases (reviewed in Davie, 1997; Davie, 1998; Davie and Chadee, 1998), and SWI/SNF chromatin-modifying complexes (Reyes et al., 1997). The mechanisms that govern the assembly of these compositely organized, multi-functional complexes at the subnuclear level may be essential for the regulation of gene expression.

Localizing regulatory proteins to specialized sites within the nucleus involves nuclear import, in situ interactions with chromatin and transcriptional co-regulators, and subnuclear targeting. Mechanisms controlling nuclear import and interactions of transcription factors with DNA and co-regulators are well defined (Gorlich and Kutay, 1999; Gorlich and Mattaj, 1996; Lemon and Tjian, 2000). However, molecular determinants that target regulatory factors to specific subnuclear domains involved in transcription remain to be identified.

Modifications in multiple parameters of nuclear architecture occur during progression of osteoblast differentiation, as reflected by subnuclear compartmentalization of gene regulatory proteins (Bidwell et al., 1993; Dworetzky et al., 1990) and alterations in chromatin structure of the bone-specific osteocalcin gene (Montecino et al., 1994; Montecino et al., 1996b; Montecino et al., 1996a; Montecino et al., 1999b; Montecino et al., 1999a). Bone-restricted expression of the osteocalcin gene provides a paradigm for defining the mechanisms underlying tissue-specific transcription in the context of nuclear and chromatin architecture. Two osteocalcin gene regulatory factors, nuclear matrix protein 1 (NMP1) and NMP2, have been identified as YY1 and Runx2/Cbfa1, respectively (Guo et al., 1995; Merriman et al., 1995). Both factors are intimately associated with control of steroid-hormone-responsive and tissue-specific transcription (Guo et al., 1997; Javed et al., 1999), suggesting functional coupling between cell signaling and nuclear architecture.

The Runx/Cbfa proteins (e.g. Runx1/AML-1, Runx2/Cbfa1) play vital roles in cellular differentiation and development. Gene ablation studies have revealed that Runx1 is required for definitive hematopoiesis whereas Runx2 is essential for bone formation (Komori et al., 1997; Otto et al., 1997; Wang et al., 1996). Runx proteins interact with the core DNA sequence (RACCRCW) through the highly conserved runt homology domain (Meyers et al., 1993; Ogawa et al., 1993). These proteins exert their effects in part by modifying chromatin organization of tissue-specific gene promoters (Gutierrez et al., 2000; Javed et al., 1999; Montecino et al., 1996b). In addition, the activities of Runx factors are modulated by interactions with coregulatory proteins (e.g. Groucho/TLE, Yes-associated protein (YAP), Smad) that contribute to the integration of cell-signaling pathways in response to physiological cues (Aronson et al., 1997; Hanai et al., 1999; Javed et al., 2000; Levanon et al., 1998; McLarren et al., 2000; Yagi et al., 1999; Zhang et al., 2000a). Runx proteins reside in discrete subnuclear foci and colocalize with transcriptional regulators which activate or repress Runx-dependent genes (Javed et al., 2000; Prince et al., 2001; Zeng et al., 1997; Zeng et al., 1998).

The identification of Runx2/Cbfa1 as a nuclear-matrix-associated tissue-specific transcription factor (Banerjee et al., 1997; Bidwell et al., 1993; Ducy et al., 1997; Merriman et al., 1995) provided the initial insight into the linkage between subnuclear compartmentalization and osteoblast differentiation. Therefore, one important question is how Runx2 is directed to specific subnuclear domains and whether intranuclear localization contributes to regulation of bone-specific genes. In the present study, we have defined a 38 amino acid segment in the C-terminus of Runx2 that is responsible for subnuclear targeting of the transcription factor. Moreover, this nuclear-matrix-targeting signal (NMTS) is sufficient to direct a heterologous protein to the nuclear-matrix-associated foci containing Runx2. Furthermore, subnuclear targeting of Runx2 contributes to transcriptional regulation of the bone-specific osteocalcin gene.


Cell cultures and transient transfections

Rat osteosarcoma ROS 17/2.8 and human cervical carcinoma HeLa cells were maintained and transfected essentially as reported previously (Javed et al., 2000).

Plasmid constructs

An epitope tag version of pcDNA 3.1 (pHA) was generated by inserting the HA-tag in the HindIII-KpnI sites to replace the His-Xpress tag of pcDNA 3.1 (Invitrogen, Carlsbad, CA). HA-tag Runx2 was constructed by cloning a cDNA encoding Runx2 in the BamHI-XbaI sites of pHA to generate pHA-Runx2 (1-528). pHA-Runx2 (1-516) was generated by digesting pHA-Runx2 (1-528) with EcoRI and XbaI followed by fill-in reaction with DNA polymerase I Klenow fragment and blunt end ligation. pHA-Runx2 (1-376) was generated by the addition of a stop codon by PCR-based site-directed mutagenesis. The Runx2 mutant Δ397-434 was constructed by PCR-based nest-deletion mutagenesis. Internal deletions of Runx2, that is, Δ400-467 and Δ433-467, were generated by digesting pHA-Runx2 with SmaI and BspmI-SmaI, respectively. To generate Gal4 DNA-binding domain (DBD) (1-147) fused with Runx2 (397-434), the aforementioned fragments of Runx2 were amplified with EcoRV-PstI sites incorporated into the primers and the digested PCR products were inserted in frame downstream of the Gal4 DBD. The reading frames of deletion mutants were confirmed by sequencing.

Nuclear extracts and electrophoretic mobility shift assay

Preparation of nuclear extracts from cells expressing proteins of interest and the protocol for electrophoretic mobility shift assays have been described (Javed et al., 1999). The wild-type Runx consensus 5′ CGAGTATTGTGGTTAATACG 3′ (Meyers et al., 1993) was synthesized using a Beckman synthesizer 2000. The Runx binding site is indicated in bold.

In situ immunofluorescence microscopy

ROS 17/2.8 or HeLa cells grown on gelatin-coated coverslips were transfected with 0.5 μg cytomegalovirus (CMV)-driven wild-type Runx2, its deletion mutants or with expression constructs for Gal4 DBD fused to the NMTS of Runx2. Cells were extracted for in situ nuclear matrix preparations and were analyzed by digital microscopy essentially as described (Javed et al., 2000). HA-tag full-length or deletion mutants of Runx2 were detected by a mouse monoclonal antibody against HA-tag at a dilution of 1:3000 (Zeng et al., 1997). Expression of the Gal4 DBD fusion constructs was detected by a mouse monoclonal antibody against Gal4 DBD (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a dilution of 1:1000. We used either Alexa 488 anti-rabbit or Alexa 568 anti-mouse secondary antibodies (Molecular Probes, Eugene, OR). To detect endogenous Runx2 in ROS 17/2.8 cells, the rabbit polyclonal antibody (Javed et al., 2001) was used at a dilution of 1:200. Mouse monoclonal antibodies were used to detect SC35, RNA processing speckles (1:500) (Spector et al., 1991), promyelocytic leukemia (PML) bodies (1:1000; Santa Cruz Biotechnology Inc.), coilin (1:100 (Smith et al., 1995)) and nucleolin (1:300; provided by P.-K. Chan, Baylor College of Medicine, TX).

Biochemical fractionation and western blotting

Cells were biochemically fractionated using a protocol previously described (Merriman et al., 1995), with several modifications. HeLa cells grown on 100 mm plates were transfected with 10 μg of full-length Runx2 or deletion constructs and subcellular fractions were prepared 24 hours after transfection. For whole-cell lysate, cells were harvested in 300 μl direct lysis buffer (2% SDS, 2 M urea, 10% glycerol, 10 mM Tris-HCl (pH 6.8), 0.002% bromophenol blue, 10 mM DTT and 1× Complete™ protease inhibitors (Roche, Indianapolis, IN)). Samples were immediately boiled for 5 minutes and stored at −70°C until used. For subcellular fractionation, cells were collected in ice-cold 1× PBS containing 1× Complete™ protease inhibitors. Cell pellets were resuspended in 300 μl CSK buffer (100 mM NaCl, 0.3 M sucrose, 10 mM Pipes, 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, pH 6.8) for 10 minutes on ice. Extracted cells were then subjected to centrifugation to collect nuclei. The supernatant containing cytosolic proteins was frozen in liquid nitrogen and stored in aliquots at −70°C. Nuclei were extracted with 300 μl digestion buffer (50 mM NaCl, 0.3 M sucrose, 10 mM Pipes, 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, pH 6.8) containing 400 U DNaseI (Roche) for 30 minutes at room temperature. DNaseI activity was stopped by adding 2 M ammonium sulfate to a final concentration of 250 mM for 5 minutes at room temperature. Extracted nuclei were centrifuged to separate soluble nuclear proteins (chromatin fraction) and insoluble nuclear-matrix-intermediate filament fraction (NM-IF). The NM-IF fraction was then boiled in 300 μl of direct lysis buffer for 5 minutes. The same volume percentage of each fraction was analyzed by 10% SDS-PAGE. Separated proteins were transferred to a PVDF membrane (Millipore) and processed for western blotting as described elsewhere (Ausubel et al., 1997). Antibodies were purchased from Santa Cruz and used in the following dilutions: monoclonal antibody against HA tag (SC-7392; 1:3000), goat polyclonal antibody against lamin B (SC-6217; 1:1000), and the corresponding horse-radish peroxidase (HRP)-conjugated secondary antibodies (SC-2042; 1:2000). Immunoreactivity was assessed using an ECL chemiluminescence kit (Amersham-Pharmacia, Piscataway, NJ).

Reporter gene activity assays

Rat osteosarcoma (ROS 17/2.8) or HeLa cells grown on six-well plates were transfected with 0.1 μg of expression vector for Runx2 or its deletion mutants along with 1 μg of −208 osteocalcin-CAT (OC-CAT), spanning one Runx-binding site (site C) (Banerjee et al., 1996; Javed et al., 1999) of the rat osteocalcin promoter. Rous sarcoma virus-luciferase (RSV-Luc) was included as an internal control for transfection efficiency. Cells were harvested 24 hours after transfection and were processed for CAT (chloramphenicol acetyl transferase) assays as described (Javed et al., 1999). All quantitation was done on the Storm PhosphorImager using ImageQuant software (ABI/Molecular Dynamics, Sunnyvale, CA). The luciferase activity was assessed with Luciferase Assay Kit (Promega, Madison, WI) from the same cell lysate. CAT values were normalized with respect to the luciferase values. The graphs are representative of three independent experiments (n=6 in each experiment) with different DNA preparations.


Runx2 resides in unique subnuclear domains

To address the mechanism that directs bone-tissue-related Runx2 protein to nuclear-matrix-associated foci, we initially assessed the subnuclear distribution of endogenous Runx2 in ROS 17/2.8 cells. As shown in Fig. 1, endogenous Runx2 protein is localized in numerous punctate subnuclear foci and remain associated with the NM-IF scaffold following detergent extraction and chromatin removal.

Fig. 1.

Endogenous Runx2 is associated with the nuclear matrix in osteoblastic cells. ROS 17/2.8 cells grown on gelatin-coated coverslips were processed for whole cell (WC) or nuclear matrix-intermediate filament (NM-IF) preparations and in situ immunofluorescence as described in Materials and Methods. Rabbit polyclonal antibody against Runx2 was used at a dilution of 1:200 (Javed et al., 2001). Secondary antibody used was Alexa 468 (goat against mouse) at a dilution of 1:800. The middle panel shows 4′,6-diamidino-2-phenylindole (DAPI) staining, which is absent in NM-IF preparation as chromatin has been removed. Right panel shows phase contrast image of the same cell.

We assessed whether Runx2 colocalizes with previously established subnuclear domains or whether it is distributed in distinct foci. Cells transiently expressing Runx2 were evaluated for the relative location of Runx2 and endogenous PML bodies (Chang et al., 1995), SC35 RNA processing speckles (reviewed by Shopland and Lawrence, 2000), nucleolar protein nucleolin (Dickinson et al., 1992) or coiled body protein coilin (Puvion-Dutilleul et al., 1995) by immunofluorescence microscopy. To facilitate antibody compatibility, we prepared a construct expressing epitope tagged Runx2 and transfected into HeLa cells that lack endogenous Runx2. As shown in Fig. 2, Runx2 does not colocalize with any of these proteins, indicating that Runx2 resides in unique subnuclear domains.

Fig. 2.

Runx2 resides in distinct subnuclear domains. HeLa cells transiently expressing Runx2 were processed for NM-IF preparation and double-label immunofluorescence to assess to what extent it colocalizes with nucleolin (A), coilin (B), SC35 (C) and PML bodies (D). Arrowheads point to distinct coilin and Runx2 domains (B) and PML bodies and Runx2 (D). Bars (2 μm) represent the relative magnification of the images.

Delineation of the NMTS of Runx2

To delineate the region of Runx2 responsible for nuclear matrix targeting, several deletion mutants of Runx2 were generated. All of the deletion mutants showed comparable levels of expression and exhibited normal DNA binding activity (Fig. 3). We analyzed the in situ subnuclear localization of these Runx2 mutants in nuclear matrix preparations of ROS 17/2.8 and HeLa cells. As shown in Fig. 4A, transiently expressed full-length Runx2 (1-528) is distributed in discrete subnuclear foci and is resistant to high salt extraction. Deletion of 12 amino acids (1-516), which removes the highly conserved VWRPY domain, has no effect on NM association of the protein (Fig. 4B). The VWRPY domain is responsible for interaction with the highly conserved Groucho/TLE class of repressors, which also associate with the NM (Chen and Courey 2000; Javed et al., 2000). The presence of Runx2 mutant lacking the VWRPY domain (1-516) in the NM-IF preparation indicates that Groucho/TLE proteins are not required for retention of Runx2 in NM-associated foci. Strikingly, removal of amino acids 377 to 528 in the C-terminus in Runx2 mutant (1-376) does not influence competency for nuclear import, but subnuclear retention of this Runx2 mutant is abrogated. Taken together, these results demonstrate that the sequences responsible for subnuclear distribution of Runx2 are distinct from those for nuclear import and that the determinants of subnuclear targeting reside in the C-terminal region of the protein (Fig. 4C).

Fig. 3.

Deletion mutants of Runx2 express at comparable levels and exhibit unaltered DNA binding activity. (A) Runx2 deletion mutants. The black box shows highly conserved runt homology domain (RHD). The dark gray box represents the amino acid sequences in Runx2 homologous to the NMTS of Runx1 whereas the C-terminal light gray box represents the highly conserved VWRPY domain. (B) HeLa cells grown in 100 mm plates were transfected at 50-60% confluence with 10 μg of the expression construct for each of the mentioned deletion mutants. The cells were harvested 24 hours after transfection in direct lysis buffer and proteins were separated by SDS-PAGE. The western blotting was carried out as described. The blots were incubated with monoclonal antibody against HA tag (Santa Cruz; dilution 1:3000) followed by incubation with HRP-conjugated secondary antibody raised against mouse (Santa Cruz; dilution 1:2000) to detect the proteins. Cdk2 antibody (1:5000) was used as an internal control. (C) HeLa cells transiently expressing mentioned deletion mutants were processed for nuclear extract preparation. Radioactively labeled Runx consensus sequence was used as probe. The mentioned proteins were used in increasing concentrations, that is, 2, 4 and 8 μg in electrophoretic mobility shift assay; EV (empty vector) indicates that cells were transfected with vector backbone.

Fig. 4.

The region responsible for subnuclear targeting of Runx2 resides in the C-terminus. ROS 17/2.8 cells grown on gelatin-coated coverslips were transfected with (A) Runx2 (1-528) (B) Runx2 (1-516) and (C) Runx2 (1-376). The cells were then processed for NM-IF preparation and in situ immunofluorescence. The coverslips were incubated with monoclonal antibody against HA tag (1:3000) followed by incubation with Alexa 568 conjugated secondary antibody (1:800) to detect the expressed proteins. Images were taken using Zeiss Axioplan digital microscope and Metamorph software was used for bio imaging. Bars (2 μm) represent the relative magnification of the images.

We applied both in situ immunofluorescence and biochemical approaches to delineate the specific amino acid sequences of Runx2 responsible for intranuclear localization (Fig. 5; Fig. 6). Several internal deletion mutants of Runx2 were examined. The results indicate that deletion of aa 400-467 abolishes the association of Runx2 (Δ400-467) with subnuclear foci in the nuclear matrix (Fig. 5A). Deletion of amino acids 397-434 eliminates NM association of Runx2 (Δ397-434) (Fig. 5B), whereas removal of amino acids 433-467 does not affect association of the protein with the NM-IF scaffold (Fig. 5C). Thus, our results establish that a 38 amino acid segment of Runx2 is required for in situ subnuclear targeting. We also monitored the biochemical partitioning of Runx2 protein among cytoplasmic, chromatin and nuclear matrix compartments by western blot analysis of subcellular fractions from cells transiently expressing Runx2 deletion mutants (Fig. 6). Mutant proteins containing amino acids 397-434 are detected in the NM-IF compartment, but mutants lacking this region [i.e. Runx2 (1-376), Runx2 (Δ400-467), Runx2 (Δ397-434)] are observed only in the cytoplasmic (CSK) and/or chromatin fractions. For comparison, lamin B, a component of the lamina pore complex, is exclusively detected in the NM-IF indicating that principal parameters of nuclear architecture have been preserved (data not shown). We conclude that deletion of the NMTS dramatically alters the subnuclear compartmentalization of Runx2 mutant proteins. The NMTS region is phylogenetically conserved in diverse vertebrate species (Fig. 7), which is consistent with the importance of the NMTS in intranuclear targeting.

Fig. 5.

Runx2 has a functional NMTS. ROS 17/2.8 cells grown on gelatin-coated coverslips were transfected with (A) Runx2 (400-467) (B) Runx2 (397-434) and (C) Runx2 (433-467). The cells were then processed for NM-IF preparation and in situ immunofluorescence as for Fig. 4. Bars (2 μm) represent the relative magnification of images.

Fig. 6.

Subcellular fractionation of HeLa cells expressing deletion mutants of Runx2. HeLa cells expressing mentioned deletion mutants were subjected to biochemical fractionation as detailed in Materials and Methods. The fractions were processed for SDS-PAGE followed by western blotting. Monoclonal antibody against HA tag was used to detect the expressed proteins.

Fig. 7.

Conservation of the nuclear matrix-targeting signal in vertebrate species. Amino acid sequence alignments of the indicated Runx2 (Cbfa1/AML3), Runx1 (Cbfa2/AML1), and Runx 3 (Cbfa3/AML2/PEBP2αA) proteins from different vertebrate species including two species of fish (Danio rerio (Danio), zebrafish; Oryzias latipes (Oryzi), Japanese killifish or medaka). Alignments were performed using CLUSTALW and graphically depicted using the GeneDoc software developed by K. B. Nicholas and H. B. Nicholas. Amino acids were colored on the basis of similarities in physiochemical properties (H,K,R, dark blue; N,Q, light blue; S,T, orange; L,I,V, dark gray, A,G, light gray; F,Y,W, maroon; M,C, yellow; P, white). None of the amino acid sequences contains negatively charged amino acids (D,E).

The NMTS of Runx2 can target a heterologous protein to Runx foci

We directly addressed the ability of the Runx2 NMTS to target a heterologous protein to NM-associated Runx2 foci. We generated a construct encoding a protein in which the NMTS is fused to the Gal4 DNA binding domain (Gal4-NMTS). Cells were transfected with constructs expressing the Gal4 DNA binding domain alone or with the Gal4-NMTS fusion protein. The subcellular distribution of these proteins was analyzed in whole-cell and NM-IF preparations by immunofluorescence microscopy (Fig. 8A). Both proteins are imported into the nucleus, which is consistent with the presence of a nuclear import signal. However, only the Gal4 protein that is fused with the 38 amino acid NMTS is retained in the NM-IF preparations. Our results establish that the Runx2 NMTS functions as an autonomous subnuclear targeting signal.

Fig. 8.

(A) The NMTS of Runx2 is functionally autonomous. HeLa cells grown on coverslips were transfected with Gal4 or Gal4-NMTS Runx2 and the cells were then processed for NM-IF preparation and in situ immunofluorescence as described. The expression of the proteins was detected by monoclonal antibody against Gal4 DBD (1:1000). (B) The NMTS of Runx2 can target a heterologous protein to the NM-associated Runx2 foci. ROS 17/2.8 cells grown on gelatin-coated coverslips were transfected with Gal4-NMTS Runx2 and were processed for double immuno labeling for endogenous Runx2 and over-expressed Gal4 DBD constructs. (C) The NMTS of Runx2 exhibits mild transactivation. The HeLa cells stably transfected with luciferase reporter carrying five Gal4 binding sites upstream of transcription initiation site were transiently transfected with Gal4 DBD or Gal4-NMTS. Cells were harvested in reporter lysis buffer 24 hours after transfection and assayed for luciferase activity as described.

To assess whether the NMTS can specify the subnuclear location of a heterologous protein, we tested the ability of the NMTS to target the Gal4 protein to the same subnuclear foci as those containing the endogenous Runx2 in osseous cells. We performed double-label immunofluorescence microscopy and compared the signals of the Gal4-NMTS protein with those for Runx2 (Fig. 8B). We observed that the NMTS of Runx2 targets Gal4 to NM-associated foci where the endogenous Runx2 resides as evidenced by a complete overlap of signals in the merged image. Therefore, our data strongly suggest that the NMTS not only mediates interactions with components of nuclear architecture but also specifies the subnuclear location of the protein.

We assessed whether subnuclear targeting of the Gal4 DBD is functionally linked to transcriptional control of a Gal4-responsive promoter. We transfected the Gal4 DBD or the Gal4-NMTS into HeLa cells containing a genomically integrated luciferase gene driven by Gal4 binding sites. As shown in Fig. 8C, the Gal4-NMTS protein mediates 2.5-fold activation relative to Gal4 DBD alone. Thus, our data indicate that the NMTS supports transcriptional activation of a Gal4-responsive promoter.

The NMTS of Runx2 contributes to activation of the bone-specific osteocalcin gene

We addressed the biological consequences of NMTS-mediated intranuclear targeting of Runx2 on osteoblast-specific gene expression. We compared the transcriptional activities of wild-type Runx2 and mutants lacking the NMTS by monitoring their ability to enhance promoter activity of the rat osteocalcin gene (Fig. 9). Wild-type Runx2 (1-528) activates osteocalcin gene transcription 7-8 fold. This response is reduced to 1.5-2 fold for the Runx2 (1-376) mutant, which lacks the entire C-terminus spanning the NMTS. This result demonstrates that the entire C-terminus of Runx2 is required for optimal physiological activity of the protein. Runx2 mutants missing only the NMTS (Δ397-434) or 68 amino acids including the NMTS (Δ400-467) exhibit dramatically reduced transactivation potential – similar to the Runx2 mutant (1-376) – compared to wild-type Runx2 (1-528). Runx2 mutants in which other segments of the C-terminus were deleted (i.e. Runx2 (Δ433-467) or Runx2 (1-516)) show only moderately reduced transactivation potential (i.e. from 7-8 fold to 4-5 fold). Interestingly, all three mutants displaying severely reduced transcriptional activity are expressed at comparable levels, are imported into the nucleus (Figs 4, 5) and have normal DNA binding activity (Fig. 3), yet exhibit compromised subnuclear targeting (Figs 4-6). These data strongly suggest that subnuclear targeting of Runx2 is obligatory for optimal transcriptional activity of the protein.

Fig. 9.

Transactivation of bone-tissue-specific marker, osteocalcin, is dependent on association of Runx2 with nuclear matrix. HeLa cells grown on six- well plates were transfected with 0.1 μg of the mentioned expression constructs along with 1 μg p208 OC CAT and 0.05 μg RSV-Luc as internal control for transfection efficiency. Cells were harvested in 300 μl of 1× Reporter Lysis Buffer (Promega) and the lysates were processed for CAT and luciferase assays as described. The CAT values were normalized with respective luciferase values and were plotted as fold activity relative to empty vector control. The graph is representative of three independent experiments each with n=6 (±s.e.m.). An example of a typical CAT assay is shown.


In the present study, we have characterized an important component of the mechanisms mediating the assembly, organization and activities of regulatory complexes within the nucleus. We report the determinants of subnuclear targeting for the bone-related Runx2 transcription factor. We demonstrate that the endogenous Runx2 in osteoblastic cells is localized in distinct NM-associated subnuclear foci that are resistant to biochemical fractionation and chromatin removal from the nucleus. Using a panel of deletion mutants, we find that a 38 amino acid sequence of Runx2 (aa 397-434), designated the NMTS, is necessary and sufficient for retention of Runx2 in subnuclear foci. The NMTS of Runx2 functions autonomously and can target a heterologous protein to subnuclear Runx2 foci. The regulatory consequences of NMTS-mediated subnuclear targeting are directly indicated by a significant contribution to transactivation of the bone-specific osteocalcin gene, which is physiologically expressed in osteoblasts. The conservation of the NMTS in the Runx1, Runx2 and Runx3 proteins of diverse vertebrate species (Fig. 7) suggests that intranuclear targeting represents a conserved function in transcriptional control of tissue-specific gene expression. The similarity in subnuclear targeting signals of the three Runx proteins indicates that similar mechanisms may govern subnuclear distribution of Runx proteins.

Components of nuclear architecture may influence the spatial organization of nucleic acids and regulatory proteins. Two types of interactions have been reported: stable interactions through nuclear-matrix-associated sequences designated MARs (Bode et al., 2000) and dynamic interactions involving transcription factors and tissue-specific nuclear matrix proteins (Bidwell et al., 1993; Dworetzky et al., 1992; van Wijnen et al., 1993). Distinct transcription factors exhibit characteristic subnuclear distributions. These regulatory proteins interact with DNA in a sequence-specific manner and associate with the components of nuclear architecture at distinct subnuclear sites. Such specific intranuclear domains can provide an environment that increases the probability of achieving a threshold for protein-DNA and protein-protein interactions to organize the regulatory machinery required for tissue-specific transcription.

The Runx family of transcription factors provides a paradigm to understand the link between transcriptional regulation and nuclear architecture. Gene ablation studies suggest that Runx2 is a principal regulator of bone formation in vivo (Komori et al., 1997; Otto et al., 1997). Recently, a nonsense mutation has been reported in exon 7, which results in expression of Runx2 lacking the NMTS (Zhang et al., 2000b). This natural mutation causes the autosomal dominant human disease the cleidocranial dysplasia (CCD), which is characterized by severe craniofacial abnormalities. The C-terminus of Runx1 containing the NMTS is a frequent target of chromosomal translocations in leukemia (Lutterbach et al., 2000; Rowley, 1998), which is consistent with physiological implications for intranuclear trafficking. Loss of the NMTS and aberrant subnuclear targeting of Runx1 has been implicated in the pathology of leukemia. Compromised subnuclear targeting of Runx2 may also contribute to the development of the CCD phenotype. Additional characterization of mechanisms that control localization of Runx proteins at subnuclear sites should contribute to understanding further the development of hematopoietic and skeletal disorders.

Our data suggest that optimal transactivation of the bone-restricted osteocalcin gene by Runx2 is dependent on subnuclear localization and/or intranuclear targeting of the protein. Interestingly, the NMTS of Runx2 we have identified in this study is contained within a larger region that has a transactivation function (Kanno et al., 1998; Thirunavukkarasu et al., 1998). Moreover, this region is responsible for the interaction of Runx2 with several proteins and integrates regulatory cues related to transforming growth factor β (TGF-β)/bone morphogenetic protein 2 (BMP2) and Yes/Crk/Src signaling pathways (Hanai et al., 1999; Yagi et al., 1999; Zhang et al., 2000a). We propose that extracellular signaling and protein-protein interactions involving the C-terminus of Runx2 and bone-specific transcriptional control may converge at subnuclear foci to optimize physiological responses.


This study was supported by National Institutes of Health grants AR45688, AR45689 and DE12528. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. The authors thank Judy Rask for editorial assistance.

  • Accepted May 21, 2001.


View Abstract